Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer
Clinical trial NCT07741630 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07741630
- Sponsor
- Peking University Third Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-15
- Primary completion
- 2027-06-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.